In PIK3CA-mutant xenografts (e.g., engineered MCF-7/H1047R models), combination therapy produced marked tumor growth inhibition and extended tumor doubling times relative to monotherapy (8, 66, 67). This evidence concerns the gene PIK3CA and neoplasm.